Strategic partnerships Leverage existing collaborations with Veloxis, Boehringer Ingelheim, and AbbVie to identify co-development and licensing opportunities in transplant, CRM diseases, and chronic inflammation, while exploring new partner capabilities to expand Tedopi and ABBV-230 applications.

Clinical momentum Capitalizing on multiple Phase 2/Phase 3 signals across Tedopi, Lusvertikimab, OSE-279, FR-104/VEL-101, and anti-SIRPα programs can attract researchers and biopharma buyers seeking first-in-class IO and I&I assets for strategic combination trials and late-stage development.

Diversified platforms Promote the four proprietary platforms as potential collaboration avenues for translational research, enabling partners to access pro-resolutive mAbs, myeloid checkpoint biology, BiCKI modularity, and mRNA therapeutic modalities for customized programs.

Commercial signals Monitor Tedopi’s ovarian cancer topline readouts and off-the-shelf potential in NSCLC to create near-term value propositions for specialty insurers, hospital systems, and clinical distributors seeking targeted IO and vaccine-based offerings.

Strategic leadership Engage with the current leadership transition and governance events to frame investor-ready business development materials, highlight strategic plan milestones, and prompt conversations with potential strategic buyers or equity partners during upcoming conferences.